EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 157 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $508,000 | -10.2% | 11,435 | 0.0% | 0.02% | +4.3% |
| Q1 2022 | $566,000 | -28.1% | 11,435 | -26.0% | 0.02% | -17.9% |
| Q4 2021 | $787,000 | -34.7% | 15,455 | -28.5% | 0.03% | -26.3% |
| Q3 2021 | $1,206,000 | +14.2% | 21,617 | -12.4% | 0.04% | +52.0% |
| Q2 2021 | $1,056,000 | +15.4% | 24,673 | +36.1% | 0.02% | +19.0% |
| Q1 2019 | $915,000 | +25.3% | 18,131 | 0.0% | 0.02% | +16.7% |
| Q4 2018 | $730,000 | +93.6% | 18,131 | +233.5% | 0.02% | +125.0% |
| Q3 2018 | $377,000 | -8.3% | 5,436 | 0.0% | 0.01% | -20.0% |
| Q2 2018 | $411,000 | +43.7% | 5,436 | 0.0% | 0.01% | +42.9% |
| Q1 2018 | $286,000 | -64.6% | 5,436 | -64.1% | 0.01% | -63.2% |
| Q4 2017 | $809,000 | +21.1% | 15,135 | +78.8% | 0.02% | +26.7% |
| Q2 2017 | $668,000 | +97.1% | 8,465 | +107.2% | 0.02% | +87.5% |
| Q1 2017 | $339,000 | +4.6% | 4,085 | 0.0% | 0.01% | +14.3% |
| Q4 2016 | $324,000 | – | 4,085 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |